Search TVTX
Travere Therapeutics, Inc.
Nasdaq · CIK 1438533
Last close56.93
Daily change+0.08 (0.14%)
10 Years gain+146.24%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TVTX · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
83.2Momentum
100.0Acceleration
100.0Confidence
84.0Annual Revenue15
Quarterly Revenue67
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality19.0 / 25
Capital Efficiency20.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 2.8554 percentage points.
Operating leverageOperating margin improved by 123.7483 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM139.92%OK
Revenue CAGR 3Y64.89%OK
Gross Margin98.75%OK
Operating Margin-3.59%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y54.97%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y5.8%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $490.73M | $480.39M | -$62.82M | $37.78M | n/a | 97.89% | -12.8% | n/a | n/a | 89.21M |
| 2025 FY Dec 31, 2024 | $233.18M | $225.43M | -$323.83M | -$237.48M | n/a | 96.68% | -138.88% | n/a | n/a | 78.89M |
| 2025 FY Dec 31, 2023 | $145.24M | $133.79M | -$388.14M | -$280.02M | n/a | 92.12% | -267.24% | n/a | n/a | 74.27M |
| 2024 FY Dec 31, 2022 | $109.46M | $105.04M | -$319.81M | -$186.29M | n/a | 95.96% | -292.17% | n/a | n/a | 63.76M |
| 2023 FY Dec 31, 2021 | $131.84M | $128.02M | -$199.43M | -$14.79M | -$19.89M | 97.1% | -151.27% | -15.09% | n/a | 59.83M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $576.09M | sum latest 4 fiscal quarters Revenue | OK | 0001438533-26-000063, 0001438533-25-000056 |
| Revenue Growth TTM | 139.92% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001438533-26-000063, 0001438533-25-000056 |
| Revenue CAGR 3Y | 64.89% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001438533-26-000014 |
| Revenue CAGR 5Y | 19.87% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001438533-26-000014 |
| Gross Profit CAGR 3Y | 65.99% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001438533-26-000014 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001438533-26-000063, 0001438533-25-000056 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 98.75% | Gross Profit / Revenue | OK | 0001438533-26-000063, 0001438533-25-000056 |
| Operating Margin | -3.59% | Operating Income / Revenue | OK | 0001438533-26-000063, 0001438533-25-000056 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001438533-26-000063 |
| Current Ratio | 4.05x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $6.16 | Revenue / Diluted Shares | OK | 0001438533-26-000063, 0001438533-25-000056 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001438533-26-000014 |